Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
33 results
D1.19 - Etoricoxib-Induced Fixed Drug Eruption: A Case Series and Assessment of Tolerance to Alternative NSAIDs
D1.27 - Delayed Hypersensitivity Reactions to Iodinated Contrast Media: Diagnostic Outcomes and Alternative Selection
D1.17 - Service Evaluation of patients with Suspected Allergic Reactions presenting to the Emergency Department of a tertiary Irish teaching hospital
D1.18 - Not Just for Kids: A Rare Case of Adult-Onset IgE-Mediated Cow’s Milk Allergy Masquerading as Drug Hypersensitivity
D1.20 - Challenges in Safe Alternative Selection in a Case of Amoxicillin-Induced Anaphylaxis
D1.21 - Three cases of Food induced Anaphylaxis - Role of Cofactors
D1.25 - Cannabis-Fruit-Veggie Syndrome: From Respiratory Symptoms to Life-Threatening Anaphylaxis
D1.26 - Egg Allergy Persistence Beyond 8 Years of Age
D1.28 - Clinical Follow-up in Radiocontrast Media–Induced Hypersensitivity Reactions: Beyond the Reaction
D1.29 - When Anaphylaxis Is Not Anaphylaxis: A Rare Differential Diagnosis in Perioperative Shock
D1.30 - Allergy Care in Adult Cystic Fibrosis Patients with Drug Hypersensitivity: A Service Evaluation at St Bartholomew’s Hospital
D1.31 - Identification of Process-Modified Allergens in Tiger Nut Milk (Horchata) as the Cause of IgE-Mediated Anaphylaxis: Molecular Evidence of Aldolase and α/β-Hydrolase Proteins
D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)
D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety
D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A
D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody
D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series
D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria
D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis
D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download